MERIT lands on Inc. 5000 for ninth straight year
MERIT CRO, Inc. was named to the 2026 Inc. 5000 list of fastest-growing private companies in America for the ninth year in a row, ranking No. 3540. The recognition highlights continued demand for the company’s clinical trial endpoint services and its EXCELSIOR platform as sponsors and CROs look for compliant, scalable trial technology.
Why it matters: - MERIT’s ninth straight Inc. 5000 appearance signals sustained growth in a competitive clinical trial services market. - The ranking matters for sponsors and CROs that rely on endpoint services and trial imaging technology to run compliant studies across regions. - The 2026 list ranks private U.S. companies by revenue growth over the 2022 to 2025 period.
What happened: - MERIT CRO, Inc. was named to the 2026 Inc. 5000 list of fastest-growing private companies in America. - The company placed No. 3540 on the list. - The recognition marks the ninth consecutive year MERIT has appeared on the Inc. 5000. - The announcement was dated August 11, 2026, from Madison, Wisconsin.
The details: - MERIT provides clinical trial endpoint services and technology. - The company works across therapeutic areas including ophthalmology, respiratory and oncology/radiology. - MERIT partners with pharmaceutical and biotech sponsors and CROs on multi-regional trials. - MERIT has offices in Madison, Wisconsin; Shanghai, China; Toronto, Canada; and Sydney, Australia. - MERIT’s EXCELSIOR platform is an FDA 510(k)-cleared, cloud-based software system for collecting and analyzing clinical and preclinical trial imaging data. - EXCELSIOR is built to meet HIPAA, 21 CFR Part 11, GDPR and HGRAC requirements. - The platform offers real-time data access, instant data transfer and global scalability. - MERIT’s website is More information. - EXCELSIOR’s product page is More information. - MERIT’s LinkedIn page is More information. - MERIT’s YouTube channel is More information. - MERIT’s X account is More information.
Between the lines: - CEO Yijun Huang framed the repeated ranking as evidence that customers trust MERIT to deliver dependable, compliant and collaborative endpoint services. - The company is also positioning EXCELSIOR as part of that value proposition for sponsors and CROs. - Repeated Inc. 5000 recognition can help reinforce credibility with life sciences customers that weigh regulatory readiness and operational reliability.
What's next: - MERIT is likely to continue using the Inc. 5000 placement as a signal of growth and market momentum. - The company will keep competing for sponsors and CROs that need endpoint services and imaging technology for global trials. - Future visibility will likely center on the performance of EXCELSIOR and MERIT’s broader clinical trial services footprint.
The bottom line: - MERIT’s ninth straight Inc. 5000 ranking underscores durable growth and a business built around regulated clinical trial support.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Wisconsin Health Press
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.